On January 19, 2023, Mr. Duncan Moore and Ms. Gail Maderis resigned as directors of Allarity Therapeutics, Inc. including their positions on each Board of Directors (the Board") committee on which they serve. In addition, on January 19, 2023, Mr. Soren G. Jensen gave notice that he will resign as a director, to be effective as of February 4, 2023. As a result of the resignations by Mr. Moore and Ms. Maderis, on January 19, 2023, the Board of the Company decreased the fixed number of authorized directors on the Board from seven (7) to five (5).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.616 USD | +6.21% | +6.98% | -94.41% |
May. 24 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
May. 06 | Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-94.41% | 190K | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ALLR Stock
- News Allarity Therapeutics, Inc.
- Allarity Therapeutics, Inc. Announces Board Changes